Diagnostics

Diagnostics

Jelly Lean gummy supplement rides viral "Pink Gelatin Trick" wave

A ClickBank-distributed ACV and BHB gummy has surged in searches after a viral pre-meal satiety trend, but counterfeit listings cloud the market.
A ClickBank-distributed ACV and BHB gummy has surged in searches after a viral pre-meal satiety trend, but counterfeit listings cloud the market.
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science

Medicus Pharma Phase 2 BCC data show dose-response at Day 57

Expanded analysis of 69 nodular BCC patients showed 200µg D-MNA achieving 55% histological clearance at Day 57, prompting FDA end-of-phase talks.
Expanded analysis of 69 nodular BCC patients showed 200µg D-MNA achieving 55% histological clearance at Day 57, prompting FDA end-of-phase talks.
The Biotech Times Editorial Team  · 
Diagnostics

NeuroSalt supplement targets neuropathy with botanical formula

A US dietary supplement brand is marketing a five-ingredient botanical capsule at peripheral neuropathy sufferers seeking alternatives to gabapentin.
A US dietary supplement brand is marketing a five-ingredient botanical capsule at peripheral neuropathy sufferers seeking alternatives to gabapentin.
The Biotech Times Editorial Team  · 
Bioinformatics
Diagnostics

Pathos AI acquires majority stake in DeuterOncology's MET inhibitor

Pathos AI used its Foundry AI platform to identify and acquire Belgium-based DeuterOncology, whose DO-2 candidate showed 100% tumour shrinkage in a small
Pathos AI used its Foundry AI platform to identify and acquire Belgium-based DeuterOncology, whose DO-2 candidate showed 100% tumour shrinkage in a small
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Philips posts 4% comparable sales growth and margin gain in Q1 2026

Royal Philips reported EUR 3.9bn in Q1 sales, 6% order intake growth and FDA clearances for four AI-powered imaging systems, reiterating its full
Royal Philips reported EUR 3.9bn in Q1 sales, 6% order intake growth and FDA clearances for four AI-powered imaging systems, reiterating its full
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science

UroGen's ZUSDURI more than doubles revenue in Q1 2026

UroGen posted $29.2m in ZUSDURI sales in Q1 2026, up 109% quarter-on-quarter, as a permanent J Code unlocked broader reimbursement access.
UroGen posted $29.2m in ZUSDURI sales in Q1 2026, up 109% quarter-on-quarter, as a permanent J Code unlocked broader reimbursement access.
The Biotech Times Editorial Team  · 
Diagnostics

Verrica Pharmaceuticals to present VP-315 abscopal BCC data at SID 2026

Phase 2 data show VP-315 reduced untreated basal cell carcinoma lesions by 67%, suggesting a systemic immune response beyond the injection site.
Phase 2 data show VP-315 reduced untreated basal cell carcinoma lesions by 67%, suggesting a systemic immune response beyond the injection site.
The Biotech Times Editorial Team  · 
Diagnostics

VVT Med publishes ScleroSafe peer-reviewed trial data

A 30-patient Mumbai study reported 92% vein occlusion at 90 days and no serious adverse events for VVT Med's catheter-directed sclerotherapy system.
A 30-patient Mumbai study reported 92% vein occlusion at 90 days and no serious adverse events for VVT Med's catheter-directed sclerotherapy system.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health

Ali Sheneamer Chief Business Development Officer at Bupa Arabia

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a healthcare solution aimed at improving patient care

Ali Sheneamer, Chief Business Development Officer at Bupa Arabia, introduced the Bupa Care Connect product, a digital-first healthcare solution aimed at improving patient care through connected services.

The Biotech Times Editorial Team  · 
Subscribe to Diagnostics